Avesta Biotherapeutics

Avesta Biotherapeutics to launch new products; unveils IPO plan

Avesta Biotherapeutics and Research (ABRPL), a joint venture between Avesthagen and Meditab Specialities Ltd (of CIPLA group), is aiming to rolls out about eight high-value, bio-similar or copied versions of off-patent biotech drugs before 2012.

ABRPL is currently working on developing drugs for anaemia, cancer and arthritis. The company stated that, after commercialization of the product, Cipla would market these products in India and in other geographies.